← Back to Clinical Trials
Recruiting NCT06755372

NCT06755372 The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06755372
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Periodontitis
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-04-01
Primary Completion 2025-07-01

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 60 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-04-01 with a primary completion date of 2025-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic kidney disease (CKD) is a significant public health issue in Egypt, leading to end-stage renal disease (ESRD). ESRD patients often suffer from oral abnormalities due to the disease and medications. Periodontitis is linked to systemic diseases, including renal disease, with inflammation playing a key role. TLR4 genetic variations may influence susceptibility to CKD and periodontitis. This study investigates the association between TLR4 \[Gly/Thr (rs2149356)\] polymorphism and chronic periodontal disease in ESRD patients in Egypt.

Eligibility Criteria

Group I: Healthy Subjects with Periodontitis Inclusion Criteria: Age: 30 to 60 years Gender: Both male and female Diagnosed with Periodontitis stage II and/or stage III Systemically healthy, no history of systemic diseases Not on long-term medications Exclusion Criteria: Smokers Individuals with any systemic disease or long-term medication use Group II: ESRD Patients with Periodontitis Inclusion Criteria: Age: 30 to 60 years Gender: Both male and female Diagnosed with end-stage renal disease (ESRD) on regular hemodialysis Diagnosed with Periodontitis stage II and/or stage III Unrelated Egyptians from a similar socioeconomic status, residing in the same geographical area Underlying type 2 diabetes mellitus Exclusion Criteria: Individuals with kidney transplants Individuals with systemic diseases other than diabetes History of malignancy Smokers

Contact & Investigator

Central Contact

Asmaa Bakr elshaf3y, PHD

✉ Asmaa.AbdAlRaouf@gu.edu.eg

📞 01000093885

Principal Investigator

Fatma E. A. Hassanein, PHD

PRINCIPAL INVESTIGATOR

king Salman Intwenational University University

Frequently Asked Questions

Who can join the NCT06755372 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 60 Years, studying Periodontitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06755372 currently recruiting?

Yes, NCT06755372 is actively recruiting participants. Contact the research team at Asmaa.AbdAlRaouf@gu.edu.eg for enrollment information.

Where is the NCT06755372 trial being conducted?

This trial is being conducted at Al Fayyum, Egypt.

Who is sponsoring the NCT06755372 clinical trial?

NCT06755372 is sponsored by Ain Shams University. The principal investigator is Fatma E. A. Hassanein, PHD at king Salman Intwenational University University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology